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Abstract
Teriflunomide (TFN) is an inhibitor of de novo pyrimidine synthesis and the active metabolite of leflunomide. Lefluno-
mide is prescribed to patients worldwide as an immunomodulatory and anti-inflammatory disease-modifying prodrug.
Leflunomide inhibited the growth of human prostate cancer xenographs in mice, and leflunomide or TFN promoted
cytostasis and/or apoptosis in cultured cells. These findings suggest that TFN could be useful in prostate cancer
chemoprevention. We investigated the possible mechanistic aspects of this tenet by characterizing the effects of
TFN using premalignant PWR-1E and malignant DU-145 human prostate epithelial cells. TFN promoted a dose- and
time-dependent cytostasis or apoptosis induction in these cells. The cytostatic effects of TFN, which were revers-
ible but not by the presence of excess uridine in the culture medium, included diminished cellular uridine levels,
an inhibition in oxygen consumption, a suppression of reactive oxygen species (ROS) generation, S-phase cell cycle
arrest, and a conspicuous reduction in the size and number of the nucleoli in the nuclei of these cells. Conversely,
TFN’s apoptogenic effects were characteristic of catastrophic mitochondrial disruption (i.e., a dissipation of mito-
chondrial inner transmembrane potential, enhanced ROS production, mitochondrial cytochrome c release, and cyto-
plasmic vacuolization) and followed by DNA fragmentation. The respiration-deficient derivatives of the DU-145 cells,
which are also uridine auxotrophs, were markedly resistant to the cytostatic and apoptotic effects of TFN, implicat-
ing de novo pyrimidine synthesis and mitochondrial bioenergetics as the primary targets for TFN in the respiration-
competent cells. These mechanistic findings advocate a role for TFN and mitochondrial bioenergetics in prostate
cancer chemoprevention.
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Introduction
Prostate cancer is one of the most frequently diagnosed tumors and the
second leading cause of cancer death among men in the United States.
Despite the routine use of diagnostic indicators for prostate cancer
development (e.g., prostate-specific antigen screening), a high cure rate
for localized disease, and an increased understanding of prostate can-
cer biology, most men who develop metastatic prostate cancer will
succumb to this disease. Thus, it is clear that effective prostate cancer
prevention strategies would spare many men the burden of diagnosis
and treatment [1].
Cancer chemoprevention uses chemical agents to modulate carcino-
genesis, thereby lowering the risk of developing invasive or clinically
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significant disease. Cancer-chemopreventive agents typically intervene
in the protracted promotion phase of carcinogenesis to inhibit or elimi-
nate premalignant cells before they progress to malignancy. This can be
accomplished by triggering cytostasis or apoptosis in the premalignant
cells [2]. Given the indolent nature of prostate tumorigenesis, chemo-
prevention would seem to be a potentially highly effective approach for
deferring malignancy [1].
Prostate tumorigenesis is coupled with an early metabolic switch in
transformed prostate epithelial cells, which is attendant with a decrease
in their citrate production through an increase in citrate oxidation by
mitochondrial aconitase. This metabolic change functionally increases
the mitochondrial bioenergetic capacity of the transformed prostate
epithelial cells, which can provide a proliferative advantage that is re-
quired to establish tumorigenesis [3].
De novo pyrimidine synthesis is indispensable in rapidly proliferating
cells to meet their increased demand for nucleic acid precursors, and this
pathway is believed to be essential for aberrant cell proliferation after
cell transformation [4]. Consequently, dihydroorotate dehydrogenase
(DHODH, EC 1.3.99.11), an enzyme associated with mitochondrial
electron transport and required for de novo pyrimidine synthesis [4], could
be an important link between the enhanced mitochondrial bioenergetics
and aberrant proliferation in transformed prostate epithelial cells.
Teriflunomide (TFN) is a redox silent coenzyme Q antagonist of
DHODH and hence an inhibitor of de novo pyrimidine synthesis
[5]. TFN’s coenzyme Q–antagonizing effect is reportedly specific for
dihydroorotate’s oxidation to orotate by DHODH because in isolated
rat liver, heart, and kidney mitochondria, the oxidation of succinate or
NADH was only marginally suppressed (i.e., by roughly 33%) at rela-
tively high concentrations (i.e., ≥100 μM) of the drug [6].
In vivo, TFN has well-known immunomodulatory and anti-
inflammatory effects, and its prodrug leflunomide (Arava) has been pre-
scribed to patients worldwide for the treatment of rheumatoid arthritis
[7,8]. Leflunomide is converted nonenzymatically to TFN after oral
ingestion, and plasma concentrations of TFN up to 300 μM have been
attained in humans [7]. With a delayed elimination half-life of approxi-
mately 2 weeks, steady-state plasma concentrations (e.g., ∼200 μM) of
TFN can be reached roughly 14 to 20 weeks after the initiation of treat-
ment with leflunomide [9], and adverse side effects are reportedly rare
even after long-term therapy with leflunomide [8–10].
Leflunomide inhibited the growth of human prostate cancer xeno-
graphs in mice [11], and leflunomide or TFN promoted cytostasis
and/or apoptosis in cultured cells [11–15]. These observations would
soundly advocate a possible role for TFN in prostate cancer chemo-
prevention. Moreover, the probability that mitochondrial bioenergetics
increases in transformed prostate epithelial cells [3] and the fact TFN
functions as a coenzyme Q antagonist and anti-DHODH agent [5]
would seemingly provide a prospective mechanistic basis for TFN-
mediated prostate cancer chemoprevention. This study was undertaken
to characterize the putative anticancer effects of TFN using premalignant
and malignant prostate epithelial cells. The information presented here
confirms that TFN can exploit the bioenergetic phenotype of these cells,
which may be an important and novel means of engaging cytostasis or
apoptosis and suppressing prostate tumorigenesis.
Materials and Methods
Cell Culture and Reagents
The premalignant PWR-1E [16] andmalignant DU-145 [17] human
prostate epithelial cells were kindly provided by Dr Rajesh Agarwal
(University of Colorado Denver School of Pharmacy, Aurora, CO).
The malignant LNCaP [17] and PC-3 [17] human prostate epithelial
cells were kindly provided by Dr Reuben Lotan (University of Texas
MD Anderson Cancer Center, Houston, TX). The PWR-1E cells were
cultured in keratinocyte growth medium (KGM), consisting of keratino-
cyte basal medium supplemented with 100 ng/ml human recombi-
nant epidermal growth factor, 0.4% bovine pituitary extract (all from
InvitrogenCorporation, Carlsbad,CA), and 1 nMof the synthetic andro-
gen R1881 (purchased from Perkin Elmer, Waltham, MA) as described
previously [18]. For certain experiments, the indicated concentrations of
uridine (purchased from Sigma-Aldrich Chemical Co, St Louis, MO)
were added to the KGM to examine the effects of this pyrimidine nucleo-
side on the PWR-1E cells with or without TFN present.
The DU-145, LNCaP, and PC-3 cells were cultured in 1:1 Dulbecco’s
modified Eagle medium/Ham’s F12 medium supplemented with 2%
fetal bovine serum (FBS; Invitrogen). Where indicated, uridine (final
concentration, 25 μM) was added to the culture medium of the
DU-145 cells to examine its effects on TFN-induced cytostasis.
The respiration-deficient (i.e., ρ0 cells lacking mitochondrial DNA)
derivatives of DU-145 cells were isolated and characterized as described
previously [18]. These cells were cultured in Dulbecco’s modified Eagle
medium containing 4.5 mg/ml D-glucose and 110 μg/ml pyruvate
(Invitrogen) supplemented with 25 μM uridine and 2% FBS. All of
the cell cultures were incubated at 37°C in humidified air containing
5% CO2. Treatment with TFN was performed on subconfluent (i.e.,
∼40% confluent) cultures.
TFN (N -(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide)
was purchased from EMDChemicals (Gibbstown, NJ). Dimethyl sulf-
oxide (Me2SO), 2′,7′-dichlorofluorescin diacetate, dihydroethidium,
and 3,3′-dihexyloxacarbocyanine iodide [DiOC6(3)] were purchased
from Sigma-Aldrich Chemical Co.
Nucleoside Quantitation in Cultured Cells
A modified version of a method published previously [19] was used
to characterize the uridine, adenosine, and guanosine content in cul-
tured cells. Briefly, approximately 2 × 106 cells were lysed in 500 μl
of a 70% methanol/deionized water solution (vol./vol.). The cell debris
was then removed through centrifugation (i.e., 1 minute at 12,000g).
The resulting supernatant was passed through an anion exchange, solid-
phase extraction cartridge (Waters QMA Accell Plus; Waters Division,
Milford, MA), and the nucleotides were eluted from the cartridge with
a 1-M KCl solution. Sweet potato type XA acid phosphatase (5 U;
Sigma-Aldrich) in acetate buffer was added to the eluent to dephos-
phorylate the nucleotides. The samples were desalted and concentrated
by a second solid-phase extraction that used a Phenomenex Strata X
cartridge (Phenomenex, Torrance, CA). The methanol eluant from
this extraction was dried under nitrogen gas and then reconstituted in
100 μl of deionized water.
A 5-μl injection volume and amobile phase consisting of a phosphate
buffer with an isocratic flow rate of 0.5 ml/min were passed through
a Thermo Scientific Hypersil GOLD aQ 1.9-μm particle size, 2.1 ×
100-mm ultra high-performance liquid chromatography column
(Thermo Scientific, San Jose, CA) connected to a Waters Acquity ultra
high-performance liquid chromatograph (Waters Division). The total
uridine, adenosine, and guanosine in the samples was quantified using
the characteristic UV absorption (i.e., 260 nm determined by photo-
diode array scanning from 210 to 400 nm) and retention time obtained
from uridine, adenosine, and guanosine standards (Sigma-Aldrich)
ranging from 5 to 500 ng (i.e., the amount injected on the column).
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The standards were processed in the same manner as the cell samples
(i.e., anion exchange, solid-phase extraction, and acid phosphatase di-
gestion). The aforementioned concentration range for the nucleoside
standards, analyzed using Waters Empore 2 software (Waters Divi-
sion), produced a linear slope for both peak heights and peak areas
(not shown).
Apoptosis Assay and Cell Cycle Analysis
Cellular DNA fragmentation was ascertained by using a hypotonic
solution of propidium iodide (PI) [18]. The cell suspensions were ana-
lyzed for PI fluorescence intensity by flow cytometry. This procedure
was also used to examine the cellular DNA content of viable cells rela-
tive to their cell cycle progression. The PI histograms were analyzed by
ModFit LT version 3.2 software (Verity Software House, Inc, Topsham,
ME), which modeled the cell cycle and provided the percentage of
G0/G1, S, and G2/M phase cells in each sample.
Assays for Determining Mitochondrial Inner Transmembrane
Potential and Reactive Oxygen Species Production
Concurrent determinations of dissipation of mitochondrial inner
transmembrane potential (ΔΨm) and reactive oxygen species (ROS)
production were conducted as described previously [20]. Twenty min-
utes before the cells were harvested, DiOC6(3) and dihydroethidium
were added directly to the culture medium (final concentrations of
40 nM and 5 μM, respectively). The cells were harvested and analyzed
immediately for DiOC6(3) and ethidium fluorescence intensity by
flow cytometry.
Flow Cytometry
The flow cytometry procedures were performed by a flow cytometer
with CXP software (FC500; Beckman Coulter, Inc, Fullerton, CA).
The experiments using flow cytometry were repeated at least two times.
Approximately 10,000 cells were analyzed in each sample.
Continuous Monitoring of ROS Production in Cultured Cells
Short-term continuous intracellular ROS generation was measured
using a microplate spectrofluorimeter assay [18]. Fluorescence emission
at 538 nm (representing the oxidation of dichlorofluorescin to 2′,7′-
dichlorofluorescein [DCF]) after excitation at 485 nm was measured
at time 0 (immediately after the addition of 2′,7′-dichlorofluorescin di-
acetate) and subsequently at 30-minute intervals during a 150-minute
period using a dual-scanning microplate spectrofluorimeter (SpectraMax
Gemini EM; Molecular Devices, Sunnyvale, CA).
Measurement of Oxygen Consumption in Cultured Cells
Oxygen consumption was measured polarographically using a Clark-
type oxygen electrode and monitor (Model 5300A Biological Oxygen
Monitor; Yellow Spring Instrument Co, Yellow Springs, OH) [18].
The oxygen consumption measurements were recorded and analyzed
using Logger Pro version 3.0 software (Vernier Software and Technology,
Beaverton, OR). The oxygen consumption rates (nmol of O2/min) were
normalized for 106 cells.
Assessment of Cytosolic Cytochrome c
Extramitochondrial cytochrome cwas determined as described previ-
ously [18]. Briefly, the PWR-1E cells were treated for 6 hours with 50,
100, or 200 μM TFN or with an equal volume of the vehicle Me2SO.
The cells were harvested, washed once with 1 ml of phosphate-buffered
saline, and gently vortexed for 30 seconds in 80 μl of ice-cold cell per-
meabilization buffer. The cell suspensions were centrifuged at 12,000g
for 5 minutes at 4°C to separate the soluble protein fraction from the
permeabilized cells. The supernatant proteins (∼50 μl) were subjected
to electrophoresis in a SDS–polyacrylamide slab gel and were evaluated
using immunoblot analysis.
Immunoblot Analysis
Cellular proteins were characterized as described previously [18]. The
cells were washed with ice-cold phosphate-buffered saline, harvested
by trypsinization, and resuspended in lysis buffer that was supple-
mented with a protease inhibitor cocktail (Sigma-Aldrich). The samples
(∼30 μg each) were separated through electrophoresis followed by trans-
fer to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA).
The membranes were probed with the antibodies for the human pro-
teins DHODH (purchased from Sigma-Aldrich), cytochrome c, or
β-actin (both purchased from Santa Cruz Biotechnology, Santa Cruz,
CA). The binding of the primary antibody was detected with a horse-
radish peroxidase–linked secondary antibody using an enhanced chemi-
luminescence kit (Amersham Biosciences Corp, Piscataway, NJ). The
DHODH and β-actin immunoblots were subjected to densitometric
analysis using ImageJ software (National Institutes of Health, Bethesda,
MD). The DHODH band intensity was normalized as a percentage of
the loading control β-actin.
Statistical Analyses
The statistical significance between the means of two groups or more
was determined using a two-sided, unpaired t test or a one-way analysis
of variance with the Dunnett post test, respectively (GraphPad InStat
version 3.0 software; GraphPad Software, Inc, San Diego, CA). Where
indicated, the results are expressed as the mean value of triplicate sam-
ples ± SD (error bars). All means ± SD were calculated with Microsoft
Excel 2003 SP2 software (Microsoft Corporation, Seattle, WA). In all
statistical analyses, the results were considered significant for P < .05.
Results and Discussion
DHODH Protein Expression Parallels the Oxygen
Consumption by Premalignant and Malignant
Prostate Epithelial Cells
It has been estimated that less than 1% of the normal epithelial cells
in the adult human prostate undergo routine cell division [21]. This
may explain why DHODH expression and biochemical activity in
normal prostate tissues were negligible compared with those observed
in transformed cells such as Ehrlich ascites tumor cells [22]. DHODH
is located in the inner mitochondrial membrane where it serves as the
rate-limiting enzyme in the de novo pathway of pyrimidine synthesis
[4]. Coenzyme Q is the proximal electron acceptor for dihydroorotate’s
oxidation to orotate by DHODH. Oxygen functions as the ultimate
electron acceptor for this reaction through electron transfer at cyto-
chrome c oxidase (i.e., complex IV). In this scenario, dihydroorotate
acts as a reducing equivalent like NADH or succinate to modulate mito-
chondrial respiration (Figure 1A).
There are currently no reported assessments of DHODH expression
or activity in transformed human prostate epithelial cells. We examined
DHODH expression in the DU-145, LNCaP, PC-3, and PWR-1E cells.
Among the premalignant PWR-1E and malignant DU-145, LNCaP,
and PC-3 prostate epithelial cells, the PWR-1E and LNCaP cells had
roughly twofold higher DHODH protein expression compared with
the DU-145 and PC-3 cells (Figure 1B). The oxygen consumption (used
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as a surrogate indicator of mitochondrial bioenergetics) by the PWR-1E
and LNCaP cells was also nearly twice that measured in an equal number
of DU-145 or PC-3 cells (Figure 1C ), indicating that DHODH ex-
pression was possibly interrelated with mitochondrial bioenergetics in
the PWR-1E and LNCaP cells.
Interestingly, the PWR-1E [16] and LNCaP [23] cells are responsive
to androgens for their proliferation, which has also been implicated
with enhanced mitochondrial bioenergetics in LNCaP cells [23]. Fur-
thermore, both PWR-1E [18] and LNCaP [24] cells have been char-
acterized as being more oxidative, with respect to their bioenergetic
capacity, than the DU-145 and/or PC-3 cells. Premalignant cells rep-
resent a very early stage of cancer development and are therefore the
envisioned target for cancer chemoprevention [2]. Consequently, we
chose to further evaluate the effects of TFN on the premalignant
PWR-1E and malignant DU-145 cells to determine whether their
relative DHODH expression and/or bioenergetic phenotype would
affect sensitivity to this agent.
TFN Causes a Dose- and/or Time-Dependent Suppression
of Cell Proliferation, Reduction in Cellular Uridine, Cell
Cycle Arrest, and Morphological Changes in PWR-1E and
DU-145 Cells
Short-term (e.g., 24-72 hours) exposures to low micromolar (e.g.,
10-200 μM) concentrations of leflunomide or TFN can promote cyto-
stasis (i.e., cause G0/G1-phase [12,13] or S-phase [11,25] cell cycle
arrest) and/or apoptosis [12,14,25] in hematopoietic cells including
normal mitogen-stimulated human T lymphocytes [13], normal human
mast cells [14], human myeloma cells [12], human chronic lymphocytic
leukemia cells [25], and murine leukemia cells [15], as well as trans-
formed murine fibroblasts [11]. However, no mechanistic data that
would propose how TFN could function as a potential cytostatic/
apoptogenic cancer-chemopreventive agent against transformed prostate
epithelial cells have emerged.
We exposed the PWR-1E cells to increasing micromolar concentra-
tions of TFN for 24 hours and examined cell number as an indicator
of proliferation or cytostasis. As illustrated in Figure 2A, increasing the
concentration of TFN promoted a concomitant decrease in cell num-
ber in these populations relative to the Me2SO-treated controls. The
50-, 100-, and 200-μM concentrations of TFN seemed to be equally
effective in triggering a seemingly complete inhibition of cell prolifera-
tion after 24 hours because the doubling time for these cells was roughly
26 hours. Even after a 48-hour exposure to 25 μM TFN, we observed
a reduction greater than 50% in cell number compared with that in the
control (not shown).
A 24-hour exposure to 25, 50, or 100μMTFNdid not seem, through
microscopic examination, to be cytotoxic to the PWR-1E cells. How-
ever, during a 24-hour exposure to 200 μM, TFN apoptotic morphol-
ogy [18] (i.e., cytoplasmic vacuolizations, cell shrinkage and rounding,
and an obvious increase in the number of floating cells in the culture
medium compared with the Me2SO-treated control cells; not shown)
could be observed in many of the PWR-1E cells. Consequently, we
decided to focus on 50 μM TFN to further investigate the cytostatic ef-
fects of this agent. To this end, we observed a time-dependent decrease
in cell number relative to the respective controls in both the PWR-1E
and DU-145 cells exposed to TFN for 24 or 48 hours (Figure 2B).
The cytostatic effect of TFN was similar in the premalignant and malig-
nant cells, indicating that their relative DHODH expression and oxygen
consumption did not profoundly affect their short-term sensitivity to
this agent. Moreover, both the DU-145 and PWR-1E cells exhibited
a similar time-dependent decrease in cellular uridine levels after a 12-
and 24-hour exposure to 50 μM TFN (Figure 2C ). The adenosine
and guanosine purine nucleoside levels remained essentially unchanged
in these cells, relative to their respective controls, during this treatment
(not shown). We examined the DHODH expression in the DU-145
and PWR-1E cells after a 24-hour exposure to 50 μM TFN and found
no change in this protein relative to the Me2SO-treated control cells
(not shown).
Exposure to 50 μM TFN also caused a time-dependent accumula-
tion of both the DU-145 and PWR-1E cells in the S phase of the cell
cycle compared with the Me2SO-treated control cells (Figure 2D). This
S-phase arrest accounted for roughly 80% of the treatment populations
after the 48-hour exposure to TFN. A summary of the cell cycle dis-
tributions for triplicate samples obtained from these 24- and 48-hour
exposures to TFN or Me2SO is presented in Figure 2E .
Figure 1. An assessment of DHODH expression and oxygen con-
sumption in transformed prostate epithelial cells. (A) A diagrammatic
depiction of DHODH in the inner mitochondrial membrane illustrat-
ing its role in mitochondrial bioenergetics and de novo pyrimidine
synthesis. Please refer to the text for additional details (I indicates
complex I; II, complex II; III, complex III; IV, complex IV; FMN, flavin
mononucleotide). (B) An immunoblot analysis of DHODH expres-
sion for the DU-145, LNCaP, PC-3, and PWR-1E cells. The DHODH
band intensity was normalized as a percentage of the loading control
β-actin using ImageJ software. (C) The oxygen consumption rates
(nmol of O2/min) were determined for approximately 10
6 cells.
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When viewed with a microscope, the DU-145 and PWR-1E cells
exposed to 50 μM TFN for 24 or 48 hours appeared morphologically
flatter, were less pleomorphic, had greater cell-to-cell contact, and
exhibited a granular cytoplasm compared with their respective control
cells (Figure 2F). There was also an obvious reduction in the size and
number of the nucleoli in the nuclei of these cells (Figure 2F, arrows).
A similar depletion of nucleoli has been observed in hepatocytes de-
rived from rats deprived of dietary nucleotides [26]. Together, these
Figure 2. TFN inhibits proliferation and decreases cellular uridine levels in PWR-1E and DU-145 cells. (A) The PWR-1E cells were treated
for 24 hours with the indicated concentrations of TFN or an equal volume of the vehicle Me2SO (control) dissolved in fresh culture medium.
The cells were harvested and counted with a hemacytometer. The relative cell number in the TFN-treated populations is presented as a
percentage of the 24-hour control. P< .001 comparedwith control. (B) The PWR-1E andDU-145 cells were cultured, harvested, and counted
as described in panel (A) after 24- and 48-hour exposures to 50 μMTFN orMe2SO (control). *P< .01 compared with the respective PWR-1E
controls; **P < .01 compared with the respective DU-145 controls. (C) An assessment of the uridine levels in the DU-145 and PWR-1E
cells after exposure to 50 μM TFN for the indicated times or Me2SO (control, 0-hour TFN exposure). *P < .01 compared with the 0-hour
DU-145 or PWR-1E control. (D) Representative PI (DNA) histograms for the treatments described in panel (B). The percentages of S-phase
cells are presented above the histograms. (E) A summary of the cell cycle analyses for the treatments described in panel (B). *P < .001
compared with the respective DU-145 controls; **P < .001 compared with the respective PWR-1E controls. (F) DU-145 and PWR-1E cells
were imaged at the indicated times after treatment with 50 μM TFN or Me2SO (control). The arrows in the differential interference contrast
images point to the cell nucleus. Scale bars, 18 μm.
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results demonstrated that the short-term cytostatic effect of TFN re-
sulted from directly decreasing de novo pyrimidine synthesis and sub-
sequent DNA synthesis in the PWR-1E and DU-145 cells.
Short-term Exposure to TFN Inhibits Mitochondrial Oxygen
Consumption and ROS Production in Premalignant and
Malignant Prostate Epithelial Cells
The modulation of de novo pyrimidine synthesis by TFN in the
transformed prostate epithelial cells should also diminish the overall
mitochondrial function in these cells. Indeed, a short-term 4-hour
exposure to TFN reduced the oxygen consumption by approximately
20% in the DU-145 cells and by roughly 30% in the PWR-1E cells
(Figure 3A). We have previously reported that the oxygen consump-
tion in these cells is sensitive to cyanide, which demonstrated that
this cellular biochemical feature was associated with mitochondrial
respiration [18].
If DHODH and de novo pyrimidine synthesis were constitutively
active in these cells as the decrease in cellular uridine levels (Figure 2C)
and the inhibition of oxygen consumption (Figure 3A) by TFN indi-
cated, this should affect not only their rate of proliferation (Figure 2B)
but also their endogenous mitochondrial ROS production [27]. This
enhanced mitochondrial ROS production could act as a feed-forward
mechanism for tumor promotion in the prostate [28]. As shown in
Figure 3B, a 4-hour exposure to TFN also suppressed the oxidation of
2′,7′-dichlorofluorescin toDCF in both theDU-145 and PWR-1E cells.
There was nearly a 50% reduction in the rate of ROS production be-
tween 30 and 150 minutes in the DU-145 cells and roughly a 65% re-
duction in the rate of ROS production during the same period in the
PWR-1E cells. Thus, TFN could be broadly classified as an antioxidant
in these cells.
Excess Uridine Is Ineffective against TFN-Induced Cytostasis
We treated the PWR-1E cells for 48 hours with 50 μM TFN,
replaced their culture medium, and examined the change in cell num-
ber and the percentage of S-phase cells in the pretreated cell popula-
tions during the subsequent 3 days to determine whether the acute
cytostatic effect of TFN could be reversed. As shown in Figure 4A,
the fresh TFN-free culture medium encouraged cell proliferation, albeit
seemingly slower than we normally observed in the PWR-1E cells, as
evidenced by an increase in the cell number relative to the cells exposed
to TFN for 48 hours. Likewise, the release from TFN allowed a con-
comitant decrease in the S-phase cells in the cell cycle as shown in
Figure 4B. The slow time-dependent recovery from the short-term
cytostatic consequences of the TFN treatment in these cells could have
resulted from a nonspecific off-target effect. It is also possible that the
disassociation of TFN from DHODH in the PWR-1E cells was a pro-
tracted process because TFN exhibits a high binding affinity for pro-
teins in vivo and in vitro [8].
Pyrimidines may be salvaged from the extracellular fluid to meet
some degree of cellular demand [4]. Although it has relatively low bio-
availability [29], uridine is reportedly the most abundant salvageable
pyrimidine nucleoside in vivo [29]. The uridine concentration of human
plasma is roughly 5 μM [29]. This concentration is estimated to be ap-
proximately five to six times lower than those in liver, kidney, and spleen
tissues that typically contain the highest levels of uridine [29]. In vitro,
approximately 1 to 5 μM uridine is reportedly present in tissue culture
medium provided the medium is supplemented with 5% to 10% non-
dialyzed FBS [30].
We wanted to determine whether uridine added to the serum-free
KGM of the PWR-1E cells would influence proliferation in these cells.
A 48-hour exposure to 5, 10, or 25 μM uridine had no obvious effect
on the number of PWR-1E cells compared with their untreated control
cells, whereas a 48-hour exposure to 50 or 100 μM uridine promoted
a mild (i.e., roughly 20%) suppression of PWR-1E cell proliferation
(Figure 5A). Interestingly, enterocyte proliferation in vitro was also re-
portedly suppressed by supraphysiological (e.g., >50 μM) concentra-
tions of uridine [31].
We next investigated the effects of 25 μM uridine on TFN-induced
cytostasis in the PWR-1E cells. Fresh KGM with or without uridine
was added to the PWR-1E cell cultures at the time of TFN treatment,
and these cells were monitored for 48 hours. As shown in Figure 5B,
without uridine present, the TFN-treated PWR-1E cells exhibited
the same morphological features that were illustrated previously in
Figure 2F. Surprisingly, when 25 μM uridine was present along with
50 μM TFN, these cells exhibited similar apoptotic morphological
Figure 3. Short-term exposure to TFN suppresses oxygen con-
sumption and ROS production in PWR-1E and DU-145 cells. (A) The
DU-145 and PWR-1E cells were treated with Me2SO (control) or
50 μM TFN in fresh culture medium for 4 hours and examined for
oxygen consumption as described in Figure 1C . *P < .05 compared
with the DU-145 control; **P< .01 compared with the PWR-1E con-
trol. (B) PWR-1E and DU-145 cells cultured in six-well tissue culture
plates were exposed to 50 μM TFN or to an equal volume of the
vehicle Me2SO (control) as described in panel (A). The medium was
removed and replaced with Krebs-Ringer buffer containing 10 μg/ml
2′,7′-dichlorofluorescin diacetate. Fluorescence emission at 538 nm
(representing DCF production) was measured immediately after
mixing (time 0) and subsequently at 30-minute intervals during
a 150-minute period. The spectrofluorimeter preformed 12 fluo-
rescence measurements per well and provided the mean DCF fluo-
rescence value.
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changes described previously for the PWR-1E cells exposed to 200 μM
TFN. Specifically, we observed the progressive development of cyto-
plasmic vacuolizations, cell shrinkage and rounding, nuclear conden-
sation, cell fragmentation, and an obvious increase in the number of
floating cells in the culture medium (not shown) of the PWR-1E cells
treated with uridine and TFN compared with the cells treated with
TFN alone or the Me2SO-treated control cells (Figure 5B). There
was also a time-dependent increase in the number of hypoploid apopto-
tic cells in the PWR-1E cells cotreated with uridine and TFN that con-
stituted approximately 40% of the treatment population after 48 hours
(Figure 5C). The basis for the acute cytotoxicity of the TFN and uri-
dine combination in the PWR-1E cells is unknown.
We have previously isolated and characterized DU-145 ρ0 cells. These
cells, by the nature of their respiration deficiency, are uridine auxotrophs.
The doubling time for the DU-145 ρ0 clones is approximately 56 hours,
whereas the parental DU-145 cells double in approximately 27 hours
without the need for supplemental uridine in their culture medium
[18]. Moreover, we detected no difference in the proliferation rate of
the DU-145 ρ0 clones after a 4-day culture in medium containing 25,
50, 100, or 200 μM uridine (not shown), suggesting that the uridine
concentration alone could not regulate proliferation in these cells.
We have also isolated ρ0 clones from cutaneous squamous cell car-
cinoma cells [32] that exhibit slow-growth characteristics similar to the
DU-145 ρ0 clones. The distinct growth characteristics displayed by
the parental cells and their ρ0 clones affirm that some aspects of mito-
chondrial bioenergetics augmented the rate of cell proliferation in the
parental cells [18]. The isolation of the ρ0 clones was not a rapid pro-
cess. It typically required approximately 8 to 10 weeks to deplete the
mitochondrial DNA and adapt the ρ0 clones to grow, albeit slowly, in
culture medium containing high glucose, uridine, and pyruvate. In ef-
fect, the up-regulation of a uridine salvage mechanism in the ρ0 clones
was coupled with a severe long-term impairment of mitochondrial bio-
energetics. As a result, the growth characteristics of the ρ0 cells in vitro
potentially emulate tumor cell growth under hypoxic conditions in vivo,
which is commonly observed in solid tumors or in metastatic tumor
sites such as the bone marrow [18].
We cultured the DU-145 cells and their ρ0 counterparts in medium
containing 25 μM uridine and assessed the effects of TFN on their
proliferation, cell cycle distribution, and cellular morphology. As illus-
trated in Figure 6A, the DU-145 cells exposed to TFN in the presence
of 25 μM uridine exhibited essentially the same degree of growth sup-
pression caused by TFN without supplemental uridine in the culture
medium (Figure 2B). Similar observations have been reported for
human chronic lymphocytic leukemia cells exposed to TFN with or
without uridine present in the culture medium [25]. Interestingly, nor-
mal mitogen-stimulated human T lymphocytes [13], normal human
mast cells [14], human myeloma cells [12], murine leukemia cells [15],
and transformed murine fibroblasts [11] examined for growth suppres-
sion and/or apoptosis induction by TFN or leflunomide were able to
avert these effects if uridine was added to their culture medium. The
apparent ability of the pyrimidine salvage pathway to overcome TFN’s
effects on cell proliferation and/or apoptosis induction in the aforemen-
tioned cells may be dependent on cell type. No apparent cytotoxic effects
of the TFN-uridine combination were detected in the DU-145 cells (not
shown). TFNalso a caused a slight antiproliferative effect in the ρ0 clones,
which, although statistically significant after 48, 72, and 96 hours, did
not emulate the short-term biological effect of TFN observed in the
parental cells (Figure 6A).
The presence of uridine could not repress the 48-hour S-phase cell
cycle arrest caused by 50 μMTFN in the DU-145 cells. This treatment
had a different effect on the cell cycle distribution of the ρ0 clones.
The ρ0 clones appeared to have slightly less S-phase cells after 48-,
72-, and 96-hour exposures to TFN (Figure 6B) with a concomitant
small accumulation of cells in the G0/G1 phase of the cell cycle (not
shown). This seemingly off-target effect could not be intimately asso-
ciated with the antiproliferative activity of TFN in the PWR-1E or pa-
rental DU-145 cells because, if this were the case, we would not expect
to detect the profound accumulation of S-phase cells after the short-
term (i.e., 24 or 48 hours) exposures to TFN. Furthermore, the ρ0
clones exposed to 50 μM TFN in the presence of 25 μM uridine for
96 hours were indistinguishable from their Me2SO-treated (i.e., con-
trol) counterparts as evidenced by their morphological (Figure 6C ),
nuclear (Figure 6C , arrows), and cell cycle (Figure 6C , insets) criteria.
Conversely, we observed conspicuous morphological (e.g., cell flat-
tening), nuclear (i.e., a marked reduction in the size and number of
the nucleoli in the nuclei of these cells), and cell cycle alterations (i.e.,
Figure 4. Cessation of TFN treatment reverts cytostasis in PWR-1E
cells. The PWR-1E cells were treated for 2 days with 50 μM TFN
dissolved in fresh KGM. The cultureswere examined for cell number
(as described in Figure 2A) and percent S-phase cells (as described
in Figure 2D). In the remaining plates, the cells received fresh KGM
after the initial 48-hour exposure to TFN. These cultures were exam-
ined for cell number (A) and percent S-phase cells (B) as described
previously during the next 3 days. *P < .01 compared with the
PWR-1E cell number after the 48-hour TFN exposure (A); *P < .01
compared with the S-phase cell population resulting from the initial
48-hour exposure to TFN (B).
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Figure 5. Uridine combined with TFN promotes cytotoxicity in PWR-1E cells. (A) The PWR-1E cells were cultured in KGM (control) or KGM
with 5, 10, 25, 50, or 100 μM uridine for 2 days. The cells were harvested and counted as described in Figure 2A. The relative cell number
in the uridine-treated cell populations is presented as a percentage of the untreated 48-hour control population. *P < .01 compared with
the untreated control. (B) DIC micrographs showing PWR-1E cells cultured in KGM containing 25 μM uridine for 48 hours, the PWR-1E cells
exposed to 50 μM TFN for 48 hours in KGM without uridine, and the PWR-1E cells exposed to 25 μM uridine and 50 μM TFN for 24 and
48 hours. Scale bars, 18 μm. (C) A summary of the hypoploid cells in the treatment populations described in panel (B). Me2SOwas included
in the control treatments without or with 25 μM uridine. *P < .001 compared with the TFN treatment alone.
Figure 6. DU-145 uridine auxotrophs oppose the acute cytostatic effects of TFN. (A) DU-145 cells and their ρ0 clones were cultured for the
indicated times in medium containing 25 μMuridine and 50 μMTFN orMe2SO (control). The cells were harvested and counted as described
in Figure 2A. *P < .001 compared with the DU-145 control; **P < .01 or #P < .05 compared with the ρ0 control. (B) The percent S-phase
cells in the indicated treatment populationswas determined as described in Figure 2D. *P< .001 for the TFN-treatedDU-145 cells compared
with the respective control without or with uridine; **P < .01 for the TFN-treated ρ0 clones compared with the ρ0 control with uridine
present. (C) The ρ0 clones were imaged 96 hours after treatment with 50 μM TFN, Me2SO (control), or culture without uridine. The arrows
in the DIC images point to the cell nucleus. Scale bars, 18 μm. The insets in the DIC images are representative PI (DNA) histograms for the
treatments indicated. The percent S-phase cells in each treatment population was determined as described in panel (B).
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S-phase cell cycle arrest) in the ρ0 clones deprived of uridine for 96 hours
(Figure 6C).
Together, the results presented in Figures 1 to 6 clearly demonstrate
that 1) bioenergetics and the de novo pathway for pyrimidine synthe-
sis were apparently crucial for the enhanced rate of cell proliferation in
the PWR-1E and parental DU-145 cells compared with the DU-145
ρ0 clones; 2) bioenergetics and the de novo pathway for pyrimidine syn-
thesis contributed to ROS production in the PWR-1E and DU-145
cells; 3) excess uridine could not reverse the short-term cytostatic effects
of TFN in the PWR-1E or DU-145 cells, demonstrating that de novo
pyrimidine synthesis and pyrimidine salvage were not functionally in-
terchangeable as a means of sustaining the typical rate of cell prolifera-
tion in these cells; 4) mitochondrial bioenergetics was required for the
effects of TFN in the respiring cells; 5) pyrimidine deficiency was asso-
ciated with the conspicuous reduction in the size and number of the
nucleoli in the nuclei of the PWR-1E and DU-145 cells exposed to
TFN or the ρ0 clones deprived of uridine; and 6) pyrimidine deficiency
was a central determinant in the S-phase cell cycle arrest detected in the
ρ0 clones deprived of uridine as well as the DU-145 and PWR-1E cells
exposed to TFN.
TFN-Induced Apoptosis Is Associated with Catastrophic
Mitochondrial Disruption in PWR-1E and DU-145 Cells
The previous data revealed that TFN modulated de novo pyrimidine
synthesis, and essentially mitochondrial function, to trigger cell cycle
arrest/cytostasis in the premalignant and malignant prostate epithelial
cells. Because we also observed a dose-dependent cytotoxic effect for
200 μM TFN in the PWR-1E cells, it was certainly possible that this
putative DHODH inhibitor and coenzyme Q antagonist was causing
an irreversible catastrophic effect to the cell’s mitochondria to trigger
cell death. In fact, leflunomide at concentrations ≥100 μM not only
markedly reduced the pyrimidine pools in mitogen-stimulated human
T lymphocytes but also conspicuously depleted the ATP and GTP
pools in these cells. These effects essentially caused a complete meta-
bolic collapse in these cells, which could account for some of the an-
cillary effects, such as kinase inactivation [11,14,15], caused by high
concentrations of leflunomide or TFN in vitro [13]. Therefore, we con-
jectured that higher (e.g., >100 μM) in vitro concentrations of TFN
could promote a profound disruption of mitochondrial function in
the transformed prostate epithelial cells as well.
Many putative cancer-chemopreventive agents can alter mitochondrial
function to trigger apoptosis in transformed cells [33], and several of the
chemopreventive agents we have examined previously, including the
synthetic retinoid N -(4-hydroxyphenyl)retinamide [32], the vanilloids
capsaicin and resiniferatoxin [34], and the rotenoid deguelin [20], pre-
sumably function as coenzymeQ antagonist to achieve their apoptogenic
effects in transformed cells. Moreover, the closed or open conformation
of the mitochondrial permeability transition pore complex is reportedly
regulated by various coenzyme Q analogs that presumably stabilize or
displace endogenous coenzyme Q, thereby regulating mitochondrial
membrane permeability [35].
Figure 7. Mitochondrial bioenergetics confers sensitivity to TFN-
induced mitochondrial disruption in premalignant and malignant
prostate epithelial cells. (A) The PWR-1E cells were exposed for
6 hours to 50, 100, or 200 μM TFN or to an equal volume of the vehi-
cle Me2SO (control). The dissipation of ΔΨm and enhanced ROS pro-
ductionwere determinedby concurrent stainingwith 40 nMDiOC6(3)
and 5 μM dihydroethidium followed by cytofluorometric analysis.
(B) An immunoblot assessment of cytosolic cytochrome c in permea-
bilized PWR-1E cells after a 12-hour exposure to 50, 100, or 200 μM
TFN or to an equal volume of the vehicle Me2SO (control). (C) The
DIC images of DU-145 cells treated for 12 hourswithMe2SO (control)
or 200 μMTFN. After treatment, the cells were stained with DiOC6(3)
and dihydroethidium as described in panel (A) followed by cytofluoro-
metric analysis. The results of this analysis are presented in the inset
figures. Scale bars, 18 μm. (D) The DU-145 ρ0 clones were exposed
for 12 hours to 200 μM TFN or to an equal volume of the vehicle
Me2SO (control), stained, and analyzed by flow cytometry as de-
scribed in panel (A).
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A sharp decrease in the retention of the cationic probe DiOC6(3)
that is accompanied by the oxidation of dihydroethidium to ethidium
can be used to monitor catastrophic mitochondrial disruption in intact
cells [20]. The control PWR-1E cells were gated, assuming they exhib-
ited high DiOC6(3) fluorescence and low ethidium fluorescence. A
6-hour exposure to 50 or 100 μMTFN did not mediate a marked shift
in the fluorescence intensity of eitherDiOC6(3) or ethidium in the sam-
ple populations. However, 200 μM TFN produced an obvious loss of
DiOC6(3) fluorescence in approximately 50% of the treatment popu-
lation accompanied by an increase in ethidium fluorescence in al-
most half of these cells (Figure 7A). Furthermore, a 12-hour exposure
to 200 μM TFN caused an obvious increase in cytosolic cytochrome
c in the PWR-1E cells relative to the lower concentrations of TFN or
the Me2SO-treated control cells (Figure 7B). Together, these results
illustrated that 200 μM TFN caused a catastrophic disruption of the
mitochondria in the PWR-1E cells sufficient to release cytochrome c
from the mitochondrial intermembrane space.
We examined oxygen consumption by the PWR-1E cells exposed
to 50, 100, and 200 μM TFN for 6 hours. The 50- and 100-μM
treatments produced a roughly 29% to 33% suppression in oxygen
consumption, respectively, compared with the Me2SO-treated control
cells (not shown), which was essentially similar to the suppression of
oxygen consumption detected in these cells after the 4-hour exposure
to 50 μM TFN (Figure 3A). Interestingly, the 6-hour exposure to
200 μM TFN promoted an increase in oxygen consumption in these
cells that measured 7.95 ± 0.44 nmol of O2/min/10
6 cells compared
with 6.12 ± 0.09 nmol of O2/min/10
6 cells in the Me2SO-treated
control cells (not shown). This increase in oxygen consumption could
have been related to the induction of ROS production triggered by the
6-hour exposure to 200 μM TFN (Figure 7A) because enhanced ROS
production reportedly increased oxygen consumption in isolated mito-
chondria that were triggered to undergo the mitochondrial permeabil-
ity transition [36].
We repeated the flow cytometry assay using the DU-145 cells. A
6-hour exposure to 200 μM TFN shifted approximately 18% of the
treatment population to low DiOC6(3) fluorescence intensity but did
not markedly influence the fluorescence intensity of ethidium (not
shown). After a 12-hour exposure, we could detect cytoplasmic vacuoliza-
tions in many of the DU-145 cells, and there was evidence of cell shrink-
age and cell rounding (Figure 7C ). Furthermore, roughly 55% of the
treatment population had shifted to low DiOC6(3) fluorescence, and
approximately 24% of these cells exhibited high ethidium fluorescence
compared with the control cells (Figure 7C , insets). These biochemical
effects were absent in the ρ0 clones exposed to 200 μMTFN for 12 hours
(Figure 7D), and we did not detect any visual signs of cytotoxicity in these
cells during a 3-day exposure to 200 μM TFN (not shown). These re-
sults further demonstrated that a high in vitro dose (i.e., 200 μM) of
TFN could promote a profound disturbance of mitochondrial function
sufficient to cause mitochondrial permeabilization in the respiring cells.
Considering its presumed redox silent quality [5], and the fact that
relatively high concentrations (i.e., ≥100 μM) of TFN diminished
Figure 8. DU-145 uridine auxotrophs are markedly resistant to
TFN-induced apoptosis. (A) Representative PI (DNA) histograms
for PWR-1E cells exposed to Me2SO (control) or to 50, 100, or
200 μM TFN for 48 hours. The gated cells detected below approxi-
mately 300 fluorescence units of PI on the linear x-axis of the rep-
resentative histograms are designated the hypoploid apoptotic
cell population. (B) A summary of the hypoploid PWR-1E cells ob-
served after the 24- or 48-hour treatments described in panel (A).
*P < .01 compared with the 24-hour control; **P < .01 compared
with the 48-hour control. (C) The parental DU-145 cells and their ρ0
clones were treated for 24, 48, or 72 hours with 200 μM TFN or
with an equal volume of the vehicle Me2SO (control). *P < .01
compared with the 24- or 48-hour DU-145 control; #P < .05 com-
pared with the 48-hour DU-145 ρ0 control; **P < .001 compared
with the 72-hour DU-145 control.
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succinate and NADH oxidation in isolated rat liver, heart, and kidney
mitochondria [6], we can only speculate that the exposure to 200 μM
TFN interrupted the normal redox function of coenzyme Q, perhaps
at a site or sites in the electron transport chain besides DHODH, to
mediate coenzyme Q redox cycling and mitochondrial damage in the
PWR-1E and DU-145 cells. We plan to investigate this hypothesis fur-
ther in future studies.
The time-dependent difference in the sensitivity to TFN-induced
mitochondrial disruption observed between the PWR-1E and DU-145
cells could be due to the differences in DHODH expression and/or
the bioenergetic phenotypes of these cells. In addition, as we mentioned
previously, TFN exhibits a high binding affinity for proteins [8]. Thus,
it is also conceivable that the 2% FBS in the culture medium of the
DU-145 cells modulated the acute cytotoxic effects of TFN.
We examined DNA fragmentation in the PWR-1E cells exposed to
50, 100, or 200 μM TFN for 24 or 48 hours and noted a dose- (Fig-
ure 8A) and time-dependent (Figure 8B) increase in hypoploid apopto-
tic cells. The 200-μM concentration of TFN was extremely effective in
this regard. Similarly, the DU-145 cells exhibited a time-dependent in-
crease in the number of hypoploid cells after treatment with 200 μM
TFN (Figure 8C), albeit this effect required more time to manifest itself
in approximately 50% or more of the treatment population compared
with the PWR-1E cells. Uridine had no effect on TFN-induced cyto-
toxicity in the DU-145 cells. A mean value of approximately 46% hypo-
ploid cells was detected in triplicate samples after a 48-hour exposure to
200 μM TFN and 25 μM uridine (not shown).
DNA fragmentation was conspicuously absent in the ρ0 clones ex-
posed to 200 μM TFN for up to 72 hours (Figure 8C), which further
implicated de novo pyrimidine synthesis and mitochondrial bioener-
getics as the primary targets for TFN-induced cytostasis and apoptosis
in the PWR-1E and parental DU-145 cells. It may be difficult to achieve
a predominately apoptotic response to TFN in transformed prostate
epithelial cells in vivo because TFN tissue concentrations are typically
lower than the average steady-state plasma concentrations of approxi-
mately 200 μM that are achieved in humans that routinely use lefluno-
mide [9].
A heightened response to mitogens such as androgens and epider-
mal growth factor coupled with enhanced mitochondrial bioenergetics
and ROS production can sustain anomalous proliferation in trans-
formed prostate epithelial cells, which can constitute a mechanistic
underpinning for prostate tumorigenesis. Given the likely collection of
factors linked to prostate cancer development and the indolent nature
of this disease, agents such as antiandrogens (e.g., 5-α-reductase in-
hibitors), anti-inflammatory agents (e.g., COX-2 inhibitors), and anti-
oxidants (e.g., vitamin E) would emerge as logical contenders in the
arena of prostate cancer chemoprevention [37]. However, to date, ex-
tensive mainstream success in this area of chemoprevention has not
been achieved.
The noted lack of practical success in prostate cancer chemopreven-
tion points to an urgent need to identify and characterize novel prostate
cancer-chemopreventive agents. Mitogens drive the rapid cell expansion
in normal lymphocytes, which can become mediators of chronic inflam-
matory diseases such as rheumatoid arthritis. Suppression of the de novo
pathway for pyrimidine synthesis in mitogen-activated T cells is believed
to be the principal mechanism of TFN with respect to its ability to
alleviate the pathologic events associated with this disease [13]. Because
prostate tumorigenesis is also associated with mitogenic, bioenergetic,
and inflammatory triggers, we anticipated that TFN could be a unique
candidate as a prostate cancer-chemopreventive agent. Our in vitro
evaluations of TFN using premalignant and malignant prostate epithe-
lial cells have shown that this agent promotes growth-inhibitory (i.e.,
cytostatic and apoptotic) as well as anti-inflammatory (e.g., anti-
oxidant) anticancer effects in these cells through the modulation of
de novo pyrimidine synthesis and mitochondrial bioenergetics. These
multifactorial properties are indeed novel. We envision that our mecha-
nistic evidence will warrant continued investigations of TFN, as well
as de novo pyrimidine synthesis and mitochondrial bioenergetics, in the
prevention of prostate cancer.
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